Regeneron Pharmaceuticals: Lymphoma, Follicular trials
The registry lists 15 Lymphoma, Follicular studies with Regeneron Pharmaceuticals as lead sponsor. 3 are open to participants now and 2 have results posted.
Phase 1 6Phase 2 3Phase 3 3No phase 3(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone LymphomaRecruitingNCT06149286Phase 3
- A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular LymphomaRecruitingNCT06091254Phase 3
- A Compassionate Use (CU) Program of OdronextamabAvailableNCT05619367
- Efficacy, Safety, and Pharmacokinetic Profiles of REGN3500 Administered to Adult Patients With Moderate-to-Severe Atopic DermatitisTerminatedNCT03738423Phase 2Results posted
- Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic DermatitisTerminatedNCT03736967Phase 2Results posted
- A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular LymphomaActive, not recruitingNCT06097364Phase 3
- Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed/Refractory Diffuse Large B-Cell LymphomaCompletedNCT05338892
- Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed or Refractory Follicular LymphomaCompletedNCT05338879
- A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)TerminatedNCT05169489Phase 1
- A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer TherapiesActive, not recruitingNCT03888105Phase 2
- Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell MalignanciesCompletedNCT02290951Phase 1
- Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's LymphomaCompletedNCT00083213Phase 1
- Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's LymphomaCompletedNCT00082823Phase 1
- VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's LymphomaCompletedNCT00045266Phase 1
- VEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin's LymphomaCompletedNCT00036946Phase 1